Founded with the mindset of combating diseases that pharma companies have failed to treat, Denali Therapeutics is currently working on therapies for Alzheimer’s, Parkinson’s and Amyotrophic Lateral Sclerosis (ALS). The company has 13 large and small molecule programs across various stages of development and two strategic pharmaceutical relationships. Denali believes that new insights into genetics and biology offer, for the first time, the opportunity to discover and develop medicines for neurodegenerative diseases.

Hosted on Acast. See acast.com/privacy for more information.